127 related articles for article (PubMed ID: 22648771)
1. Vector systems for prenatal gene therapy: principles of non-viral vector design and production.
Wong SP; Argyros O; Harbottle RP
Methods Mol Biol; 2012; 891():133-67. PubMed ID: 22648771
[TBL] [Abstract][Full Text] [Related]
2. Vector systems for prenatal gene therapy: principles of retrovirus vector design and production.
Howe SJ; Chandrashekran A
Methods Mol Biol; 2012; 891():85-107. PubMed ID: 22648769
[TBL] [Abstract][Full Text] [Related]
3. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
4. Vector systems for prenatal gene therapy: principles of adenovirus design and production.
Alba R; Baker AH; Nicklin SA
Methods Mol Biol; 2012; 891():55-84. PubMed ID: 22648768
[TBL] [Abstract][Full Text] [Related]
5. Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and non-viral transfection.
Douglas KL
Biotechnol Prog; 2008; 24(4):871-83. PubMed ID: 18335953
[TBL] [Abstract][Full Text] [Related]
6. Vector systems for prenatal gene therapy: choosing vectors for different applications.
Coutelle C; Waddington SN
Methods Mol Biol; 2012; 891():41-53. PubMed ID: 22648767
[TBL] [Abstract][Full Text] [Related]
7. Monitoring for potential adverse effects of prenatal gene therapy: use of large animal models with relevance to human application.
Mehta V; Abi-Nader KN; Carr D; Wallace J; Coutelle C; Waddington SN; Peebles D; David AL
Methods Mol Biol; 2012; 891():291-328. PubMed ID: 22648778
[TBL] [Abstract][Full Text] [Related]
8. Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus.
Waddington SN; Buckley SM; Bernloehr C; Bossow S; Ungerechts G; Cook T; Gregory L; Rahim A; Themis M; Neubert WJ; Coutelle C; Lauer UM; Bitzer M
Gene Ther; 2004 Apr; 11(7):599-608. PubMed ID: 14724676
[TBL] [Abstract][Full Text] [Related]
9. Current status of polymeric gene delivery systems.
Park TG; Jeong JH; Kim SW
Adv Drug Deliv Rev; 2006 Jul; 58(4):467-86. PubMed ID: 16781003
[TBL] [Abstract][Full Text] [Related]
10. Non-viral and viral vectors for gene therapy.
Boulaiz H; Marchal JA; Prados J; Melguizo C; Aránega A
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(1):3-22. PubMed ID: 16171561
[TBL] [Abstract][Full Text] [Related]
11. Towards safe, non-viral therapeutic gene expression in humans.
Glover DJ; Lipps HJ; Jans DA
Nat Rev Genet; 2005 Apr; 6(4):299-310. PubMed ID: 15761468
[TBL] [Abstract][Full Text] [Related]
12. Efficient infection and persistence of a herpesvirus saimiri-based gene delivery vector into human tumor xenografts and multicellular spheroid cultures.
Smith PG; Burchill SA; Brooke D; Coletta PL; Whitehouse A
Cancer Gene Ther; 2005 Mar; 12(3):248-56. PubMed ID: 15540115
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy: progress and challenges.
Meyer F; Finer M
Cell Mol Biol (Noisy-le-grand); 2001 Dec; 47(8):1277-94. PubMed ID: 11838948
[TBL] [Abstract][Full Text] [Related]
14. What role can chemistry play in cationic liposome-based gene therapy research today?
Kostarelos K; Miller AD
Adv Genet; 2005; 53():71-118. PubMed ID: 16240991
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
16. Non-viral gene therapy: polycation-mediated DNA delivery.
Thomas M; Klibanov AM
Appl Microbiol Biotechnol; 2003 Jul; 62(1):27-34. PubMed ID: 12719940
[TBL] [Abstract][Full Text] [Related]
17. Polyethylenimine (PEI).
Demeneix B; Behr JP
Adv Genet; 2005; 53():217-30. PubMed ID: 16240995
[TBL] [Abstract][Full Text] [Related]
18. Somatic gene therapy. Present situation and future perspective.
Gottschalk U; Chan S
Arzneimittelforschung; 1998 Nov; 48(11):1111-20. PubMed ID: 9850435
[TBL] [Abstract][Full Text] [Related]
19. Hybrid vector designs to control the delivery, fate and expression of transgenes.
Lam PY; Breakefield XO
J Gene Med; 2000; 2(6):395-408. PubMed ID: 11199260
[TBL] [Abstract][Full Text] [Related]
20. Development of a FLP/frt system for generating helper-dependent adenoviral vectors.
Ng P; Beauchamp C; Evelegh C; Parks R; Graham FL
Mol Ther; 2001 May; 3(5 Pt 1):809-15. PubMed ID: 11356086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
